Item 1.01 Entry into a Material Definitive Agreement.
On July 11, 2022, Ionis Pharmaceuticals, Inc. (the "Company") issued a press
release announcing that the Company's partner, Roche, licensed IONIS-FB-LRx, an
investigational antisense medicine, and will advance the medicine into a Phase 3
clinical study in patients with immunoglobulin A nephropathy (IgAN). A copy of
this press release is attached as Exhibit 99.1 to this Current Report and
incorporated herein by reference.
In connection with such license, on July 8, 2022, the Company and Roche entered
into an amendment to the Factor B Development, Collaboration, Option and License
Agreement dated October 9, 2018.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated July 11, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses